Published in Nat Biotechnol on October 01, 2010
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res (2011) 3.36
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell (2015) 2.45
Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell (2014) 2.28
Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr (2012) 1.80
Epigenetics in liver disease. Hepatology (2014) 1.77
Epigenetic mechanisms in neurological disease. Nat Med (2012) 1.74
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood (2011) 1.67
Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res (2012) 1.60
MSC Transplantation Improves Osteopenia via Epigenetic Regulation of Notch Signaling in Lupus. Cell Metab (2015) 1.49
Gene induction and repression during terminal erythropoiesis are mediated by distinct epigenetic changes. Blood (2011) 1.43
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency. Sci Transl Med (2013) 1.36
The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci (2013) 1.30
High resolution methylome map of rat indicates role of intragenic DNA methylation in identification of coding region. PLoS One (2012) 1.29
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods (2016) 1.24
FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure. Nat Commun (2012) 1.21
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio (2013) 1.15
Interactions between epigenetics and metabolism in cancers. Front Oncol (2012) 1.11
Epigenetics in diabetic kidney disease. J Am Soc Nephrol (2011) 1.09
New lysine methyltransferase drug targets in cancer. Nat Biotechnol (2012) 1.08
Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet (2012) 1.07
Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death. Exp Neurol (2012) 1.07
Cell signaling, post-translational protein modifications and NMR spectroscopy. J Biomol NMR (2012) 1.06
Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ. PLoS Pathog (2012) 1.04
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One (2012) 1.03
Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol (2012) 1.03
Linking cell signaling and the epigenetic machinery. Nat Biotechnol (2010) 1.03
Interplay between Epigenetics and Genetics in Cancer. Genomics Inform (2013) 1.03
An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases. J Mol Biol (2011) 1.01
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett (2012) 1.00
Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers (Basel) (2011) 1.00
Structural insight into how the human helicase subunit MCM2 may act as a histone chaperone together with ASF1 at the replication fork. Nucleic Acids Res (2015) 1.00
Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol (2012) 0.99
Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog (2013) 0.97
Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol (2013) 0.96
Human genetics and genomics a decade after the release of the draft sequence of the human genome. Hum Genomics (2011) 0.95
LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastric Cancer (2012) 0.95
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol (2014) 0.95
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene (2012) 0.95
The dynamics of HCF-1 modulation of herpes simplex virus chromatin during initiation of infection. Viruses (2013) 0.94
Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget (2013) 0.94
Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription. J Cell Biochem (2012) 0.92
Druggability of methyl-lysine binding sites. J Comput Aided Mol Des (2011) 0.92
Transcriptional control of cancer metastasis. Trends Cell Biol (2013) 0.92
Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol (2015) 0.92
Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol (2013) 0.92
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor. Adv Protein Chem Struct Biol (2012) 0.91
Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Exp Neurol (2015) 0.91
Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer (2016) 0.90
Epigenetic mechanisms in stroke and epilepsy. Neuropsychopharmacology (2012) 0.90
Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein. J Biol Chem (2014) 0.89
Bringing epigenetics into the diagnostics of the andrology laboratory: challenges and perspectives. Asian J Androl (2014) 0.88
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. Onco Targets Ther (2013) 0.88
Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1. ACS Chem Biol (2015) 0.87
HPV-positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation. Cancer Med (2014) 0.87
Distinct roles of DNMT1-dependent and DNMT1-independent methylation patterns in the genome of mouse embryonic stem cells. Genome Biol (2015) 0.87
Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer. Br J Cancer (2013) 0.87
Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med (2016) 0.87
Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem Biol (2014) 0.86
Epigenetic therapy for breast cancer. Int J Mol Sci (2011) 0.86
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer (2014) 0.86
Sulforaphane causes a major epigenetic repression of myostatin in porcine satellite cells. Epigenetics (2012) 0.85
Alterations of DNA methylome in human bladder cancer. Epigenetics (2013) 0.85
Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. Oncotarget (2015) 0.85
Potential for pharmacological manipulation of human embryonic stem cells. Br J Pharmacol (2013) 0.85
Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene (2015) 0.84
The path to epigenetic treatment of memory disorders. Neurobiol Learn Mem (2011) 0.83
The epigenome of synovial fibroblasts: an underestimated therapeutic target in rheumatoid arthritis. Arthritis Res Ther (2014) 0.83
Design, synthesis, and kinetic analysis of potent protein N-terminal methyltransferase 1 inhibitors. Org Biomol Chem (2015) 0.83
Epigenetic regulation of microRNAs in gastric cancer. Dig Dis Sci (2013) 0.83
The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol (2012) 0.82
Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med (2016) 0.82
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J Immunol Res (2014) 0.82
Blood transcriptomics of drug-naïve sporadic Parkinson's disease patients. BMC Genomics (2015) 0.82
SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in PC3 prostate cancer cells. Oncogenesis (2014) 0.81
The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition. Nucleic Acids Res (2014) 0.81
Can genome engineering be used to target cancer-associated enhancers? Epigenomics (2014) 0.81
Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth. Cancer Res (2016) 0.81
Demethylation of microRNA-142 induced by demethylation agents plays a suppressive role in osteosarcoma cells. Oncol Lett (2015) 0.81
The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. Clin Epigenetics (2016) 0.81
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Crit Rev Oncog (2015) 0.81
Effect of maternal cardiovascular conditions and risk factors on offspring cardiovascular disease. Circulation (2014) 0.81
Imprinted genes and the environment: links to the toxic metals arsenic, cadmium, lead and mercury. Genes (Basel) (2014) 0.81
Histone methyltransferase and histone methylation in inflammatory T-cell responses. Immunotherapy (2013) 0.81
Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells. PLoS One (2013) 0.81
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer (2013) 0.80
In vivo epigenetic effects induced by engineered nanomaterials: A case study of copper oxide and laser printer-emitted engineered nanoparticles. Nanotoxicology (2015) 0.80
Genetic and Epigenetic Regulation in Age-related Macular Degeneration. Asia Pac J Ophthalmol (Phila) (2015) 0.80
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. Cancer Res (2015) 0.80
Linking epithelial-to-mesenchymal-transition and epigenetic modifications. Semin Cancer Biol (2012) 0.80
Epigenetics advancing personalized nanomedicine in cancer therapy. Adv Drug Deliv Rev (2012) 0.80
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
The epigenomics of cancer. Cell (2007) 30.91
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (2009) 20.49
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet (2009) 18.90
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet (2006) 10.47
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Epigenetics in cancer. Carcinogenesis (2009) 7.49
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A (2003) 5.56
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell (2007) 5.49
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature (2006) 4.74
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet (2008) 4.40
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A (2000) 3.65
Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet (2007) 3.65
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol (2006) 3.50
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol (2009) 3.05
The emerging field of dynamic lysine methylation of non-histone proteins. Curr Opin Genet Dev (2008) 3.01
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem (2010) 2.64
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One (2008) 2.52
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol (2009) 2.50
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Understanding microRNAs in neurodegeneration. Nat Rev Neurosci (2009) 2.22
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res (2007) 2.00
Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs (2009) 1.99
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia (2008) 1.97
Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol Endocrinol (2009) 1.95
The role of DNA methylation in the central nervous system and neuropsychiatric disorders. Int Rev Neurobiol (2009) 1.89
MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer (2009) 1.88
Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res (2009) 1.87
The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol (2010) 1.83
A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene (1999) 1.80
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep (2007) 1.62
Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol (2007) 1.61
Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans (2004) 1.49
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci (2009) 1.44
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer (2007) 1.44
Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res (2008) 1.41
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res (2007) 1.40
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer (2009) 1.34
The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther (2008) 1.31
Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res (2009) 1.28
Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther (2008) 1.28
IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene (2009) 1.27
Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci U S A (2009) 1.27
Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res (2007) 1.25
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother (2008) 1.21
Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD (2005) 1.17
Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem (2009) 1.17
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res (2009) 1.12
Global levels of histone modifications predict prostate cancer recurrence. Prostate (2010) 1.11
DNA methylation as a biomarker in breast cancer. Future Oncol (2009) 1.09
Primers on chromatin. Nat Struct Mol Biol (2007) 1.05
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res (2009) 1.02
Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol (2009) 0.98
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res (2001) 0.98
Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol (2008) 0.96
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A (2004) 4.39
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
The CpG island searcher: a new WWW resource. In Silico Biol (2003) 3.42
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
DNA methylation: the nuts and bolts of repression. J Cell Physiol (2007) 3.00
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
Epigenetics and microRNAs. Pediatr Res (2007) 2.52
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Epigenetic changes in cancer. APMIS (2007) 1.96
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet (2011) 1.83
DNA methylation and cellular reprogramming. Trends Cell Biol (2010) 1.77
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res (2004) 1.68
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol (2004) 1.68
Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res (2003) 1.62
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol (2011) 1.58
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet (2011) 1.56
OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci U S A (2011) 1.51
Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet (2006) 1.48
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol (2005) 1.41
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res (2007) 1.40
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res (2007) 1.40
Emergency Department utilisation: a natural experiment. N Z Med J (2009) 1.39
Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol (2011) 1.34
Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res (2002) 1.32
DNA methylation and cancer. Prog Drug Res (2011) 1.24
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. Mol Biol Evol (2003) 1.20
Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer (2005) 1.18
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood (2011) 1.17
Genome-wide nucleosome map and cytosine methylation levels of an ancient human genome. Genome Res (2013) 1.12
Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res (2005) 1.12
Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci (2005) 1.11
Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res (2013) 1.09
Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet (2012) 1.07
Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One (2010) 1.07
Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF. Nucleic Acids Res (2009) 1.07
Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). Methods (2002) 1.06
Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods (2002) 1.06
RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res (2008) 1.05
Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells. Gene (2002) 1.04
Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids (2005) 0.99
A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res (2014) 0.99
The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle (2009) 0.94
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 0.94
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol (2004) 0.94
At the tipping point for epigenetic therapies in cancer. J Clin Invest (2014) 0.94
Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in patients with breast cancer. AJR Am J Roentgenol (2012) 0.93
Methylation-sensitive single-molecule analysis of chromatin structure. Curr Protoc Mol Biol (2010) 0.93
Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol (2009) 0.91
Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer (2013) 0.90
A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res (2012) 0.87
SNF5 is an essential executor of epigenetic regulation during differentiation. PLoS Genet (2013) 0.87
Meddling with methylation. Nat Cell Biol (2003) 0.86
Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics (2011) 0.86
Radiopaque coil insertion into breast cancers prior to neoadjuvant chemotherapy. Breast (2005) 0.86
Patch clamp recording from enteric neurons in situ. Nat Protoc (2011) 0.82
Reprogramming of the human intestinal epigenome by surgical tissue transposition. Genome Res (2014) 0.80
Percutaneous removal of sentinel lymph nodes in a swine model using a breast lesion excision system and contrast-enhanced ultrasound. Eur Radiol (2011) 0.79